search
Back to results

Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures

Primary Purpose

COVID-19 (SARS-CoV-2)

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Participate in a massive musical event
Sponsored by
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for COVID-19 (SARS-CoV-2) focused on measuring SARS-CoV-2, COVID-19, Coronavirus, Superspreading event, Concert

Eligibility Criteria

18 Years - 59 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults (age 18-59 years) with interest to attend the scheduled musical event who agree to participate in the study after signing the informed consent, including explicit acceptance of the measures implemented to reduce the risk of transmission of SARS-CoV-2.
  • Negative antigen test performed up to 24 h before the event, in nasopharyngeal swab.

Exclusion Criteria:

  • Hypertension
  • Diabetes Mellitus.
  • Ischemic heart disease.
  • Any type of Cancer in active treatment.
  • Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
  • Have a positive test for detection of SARS-CoV-2 by the rapid antigen test
  • Who have a body temperature higher than 37.0º on the same day of the event
  • Who have a confirmed diagnosis for SARS-CoV-2 in the two weeks prior to the event
  • Report any symptoms suggestive of a SARS-CoV-2 infection in the 10 days prior to the study
  • Who have been in contact with a person with a confirmed diagnosis of SARS-CoV-2 infection within two weeks prior to the event.
  • Living with a person over 70 years of age (inclusive).

Sites / Locations

  • Germans Trias i Pujol Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Experimental group

Control Group

Arm Description

Participate in a massive musical event

Not participate in a massive musical event

Outcomes

Primary Outcome Measures

Incidence rate of people infected with SARS-CoV-2 8 days after randomization
Incidence rate of people infected with SARS-CoV-2 8 days after randomization, detected by PCR in nasopharyngeal aspirate, on the experimental and the control group.

Secondary Outcome Measures

SARS-CoV-2 genome sequence
Nasopharyngeal swab samples will be stored in case SARS-CoV-2 infections are documented for sequencing purposes to assess the possibility of spreading clusters during the event. Data will be matched with a Global Positioning System (GPS) smart phone tracking localization during the concert.
Incidence rate of appearance of symptoms compatible with COVID 19
Incidence rate of appearance of symptoms compatible with COVID 19 in those attending the event after 10 days (D10).
Time spent in testing the total number of participants in the study.
Time spent in testing the total number of participants in the study.
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva, in positive cases by this technique.
Presence of viable SARS-CoV-2 from cell culture
Presence of viable SARS-CoV-2 from cell culture in all cases with negative Ag and positive PCR.
Satisfaction in relation to the test procedure
Assessment of the results obtained on satisfaction in relation to the test procedure of those attending the event through a questionnaire. Questions: I have had all the necessary prior information to participate in this study I have felt properly cared for by the health personnel I have felt properly cared for by the room staff I have behaved naturally without feeling conditioned by the measures of the protocol during the event I have been able to enjoy the performance in a satisfactory way I will attend other leisure events in closed spaces following this same protocol It can be answered with a scale from 0 to 10 (0 not satisfied at all, 10 extremely satisfied)

Full Information

First Posted
December 9, 2020
Last Updated
February 5, 2021
Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborators
Dr. Bonaventura Clotet Sala, Dr. Josep Mª LLibre Codina, Dr. Boris Revollo Barriga, Dra. Lidia Ruiz Tabuenca, Dr. Ignacio Blanco Guillermo, Dra. Andrea Alemany Ortiz, Dr. Roger Paredes Deiros
search

1. Study Identification

Unique Protocol Identification Number
NCT04668625
Brief Title
Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures
Official Title
Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
November 30, 2020 (Actual)
Primary Completion Date
December 20, 2020 (Actual)
Study Completion Date
January 8, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Collaborators
Dr. Bonaventura Clotet Sala, Dr. Josep Mª LLibre Codina, Dr. Boris Revollo Barriga, Dra. Lidia Ruiz Tabuenca, Dr. Ignacio Blanco Guillermo, Dra. Andrea Alemany Ortiz, Dr. Roger Paredes Deiros

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread globally, representing a serious threat to public health. While waiting for highly effective treatments or the development of an effective vaccine, it is necessary to reactivate key economic activities that are related to leisure and culture in an environment that is safest for the participants. The use of a rapid screening test for SARS-CoV-2 viral antigens with high sensitivity could be a useful tool to detect asymptomatic SARS-CoV-2 infected people, and thus be able to carry out events related to leisure in a safe environment. The aim of this study is to make a mass screening of asymptomatic infection of an (i) experimental group (public attending a massive mass musical show) and (ii) a control group (they will not enter the event) prior to entering to the event. Randomization 1: 1 by random blocks of the participants with a negative antigen test in the experimental group (attending the event) and the control group (they will not enter the event). Control with a new Polymerase Chain Reaction (PCR) test 8 days after the event (D8) in the participants of both randomized groups Control of the appearance of symptoms through a questionnaire 10 days after the event (D10), in the participants of both groups with a negative result on day 8. Validation of a rapid antigen detection test by comparison with the PCR technique. The indoor activity will include an array of measures designed to reducing the contagion risk, including: mandatory wearing a mask during the event, restricted outdoor areas of bar and smoking, enhanced ventilation of the whole indoor area, and avoiding queues. All subjects will have downloaded an app in their smart phones to help contact and place tracing during the event, to trace potential transmissions. This app will remain active for 8 days, until the last virologic control. The inclusion criteria will allow only subjects with an age <60 years, without comorbidities, and who do not live with old adults in their homes, to further reduce the risk of potential complications and transmission to at risk individuals.
Detailed Description
The coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan in December 2019 and has spread globally, representing a serious threat to public health. While 80% of patients are asymptomatic or have a mild illness, 20% develop a severe illness. The predominant symptoms include fever, cough, and myalgia. Mild disease can resolve without medical attention or it can progress to pneumonia and respiratory failure requiring hospitalization. Patients can rapidly progress to acute respiratory distress syndrome (ARDS) with multiple organ dysfunction and death. The degree to which the virus is infectious during the incubation period is uncertain, but it has been shown that the pharynx reaches peak viral load before day 5, and this peak viral load is 1,000 times higher than in severe acute respiratory syndrome coronavirus (SARS-CoV). This active and high viral clearance from the pharynx at a time when symptoms are still mild makes the transmission of SARS-CoV-2 more efficient than that of SARS-CoV. Later in the disease, COVID-19 resembles SARS in terms of replication in the lower respiratory tract. The decrease in viral load appears to be slow, and there is no sudden shedding of the virus at the time of seroconversion. Seroconversion, at the beginning of week 2, has been observed to coincide with a slow but steady decrease in sputum viral load. Prolonged viral shedding in sputum is relevant not only for infection control in hospitals and discharge management, but also for asymptomatic people who can transmit the virus for longer periods after infection. Although it is true that the majority of people infected by SARS-CoV-2 will have a benign course with few symptoms, approximately 20% will require hospitalization and 5% will present serious complications and admission to an intensive care unit, this is it translates into a saturation and collapse of health systems, with a high percentage of mortality in relation to it. Unprecedented confinement measures have been implemented that have been effective in containing the progression of the number of infections, but these have had a great social and economic impact, among others with a paralysis of most of the activities related to leisure (concerts , music festivals, theaters, etc.) that are an important component in the economy of most of the countries of the European community. While waiting for highly effective treatments or the development of an effective vaccine, it is necessary to reactivate key economic activities that are related to leisure and culture in an environment that is safest for the participants. The use of a rapid screening test for SARS-CoV-2 viral antigens with high sensitivity could be a useful tool to detect asymptomatic SARS-CoV-2 infected people, and thus be able to carry out events related to leisure in a safe environment. It is necessary to implement versatile circuits in which diagnoses with rapid tests can be carried out in the same place of the events in a massive way and to be able to communicate the results of the tests to the assistants at the same time, in order to do this screening of people that they give negative and carry out activities with them in a safe environment for all participants. The aim of this study is to make a mass screening of asymptomatic infection of an (i) experimental group (public attending a massive mass musical show) and (ii) a control group (they will not enter the event) prior to entering to the event. Randomization 1: 1 by random blocks of the participants with a negative antigen test in the experimental group (attending the event) and the control group (they will not enter the event). Control with a new PCR test 8 days after the event (D8) in the participants of both randomized groups Control of the appearance of symptoms through a questionnaire 10 days after the event (D10), in the participants of both groups with a negative result on day 8. Validation of a rapid antigen detection test by comparison with the PCR technique. The indoor activity will include an array of measures designed to reducing the contagion risk, including: mandatory wearing a mask during the event, restricted outdoor areas of bar and smoking, enhanced ventilation of the whole indoor area, and avoiding queues. All subjects will have downloaded an app in their smart phones to help contact and place tracing during the event, to trace potential transmissions. This app will remain active for 8 days, until the last virologic control. The inclusion criteria will allow only subjects with an age <60 years, without comorbidities, and who do not live with old adults in their homes, to further reduce the risk of potential complications and transmission to at risk individuals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19 (SARS-CoV-2)
Keywords
SARS-CoV-2, COVID-19, Coronavirus, Superspreading event, Concert

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
All participants will be screened for a rapid Ag SARS-CoV-2 test detection. All negative subjects will be randomized to an experimental arm (participate in a massive musical event) or to a control arm (not participate in a massive musical event).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1000 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
Participate in a massive musical event
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Not participate in a massive musical event
Intervention Type
Behavioral
Intervention Name(s)
Participate in a massive musical event
Intervention Description
Participate in a massive musical event
Primary Outcome Measure Information:
Title
Incidence rate of people infected with SARS-CoV-2 8 days after randomization
Description
Incidence rate of people infected with SARS-CoV-2 8 days after randomization, detected by PCR in nasopharyngeal aspirate, on the experimental and the control group.
Time Frame
At 8 days
Secondary Outcome Measure Information:
Title
SARS-CoV-2 genome sequence
Description
Nasopharyngeal swab samples will be stored in case SARS-CoV-2 infections are documented for sequencing purposes to assess the possibility of spreading clusters during the event. Data will be matched with a Global Positioning System (GPS) smart phone tracking localization during the concert.
Time Frame
At 8 days
Title
Incidence rate of appearance of symptoms compatible with COVID 19
Description
Incidence rate of appearance of symptoms compatible with COVID 19 in those attending the event after 10 days (D10).
Time Frame
At 10 days
Title
Time spent in testing the total number of participants in the study.
Description
Time spent in testing the total number of participants in the study.
Time Frame
At day 0
Title
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
Description
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 compared to PCR in asymptomatic subjects.
Time Frame
At day 0
Title
Comparison of the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva
Description
We will compare the diagnostic sensitivity of rapid antigen tests for SARS-CoV-2 using a nasopharyngeal swab sample compared to sample obtained trough saliva, in positive cases by this technique.
Time Frame
At day 0
Title
Presence of viable SARS-CoV-2 from cell culture
Description
Presence of viable SARS-CoV-2 from cell culture in all cases with negative Ag and positive PCR.
Time Frame
At day 0
Title
Satisfaction in relation to the test procedure
Description
Assessment of the results obtained on satisfaction in relation to the test procedure of those attending the event through a questionnaire. Questions: I have had all the necessary prior information to participate in this study I have felt properly cared for by the health personnel I have felt properly cared for by the room staff I have behaved naturally without feeling conditioned by the measures of the protocol during the event I have been able to enjoy the performance in a satisfactory way I will attend other leisure events in closed spaces following this same protocol It can be answered with a scale from 0 to 10 (0 not satisfied at all, 10 extremely satisfied)
Time Frame
At 10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults (age 18-59 years) with interest to attend the scheduled musical event who agree to participate in the study after signing the informed consent, including explicit acceptance of the measures implemented to reduce the risk of transmission of SARS-CoV-2. Negative antigen test performed up to 24 h before the event, in nasopharyngeal swab. Exclusion Criteria: Hypertension Diabetes Mellitus. Ischemic heart disease. Any type of Cancer in active treatment. Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Have a positive test for detection of SARS-CoV-2 by the rapid antigen test Who have a body temperature higher than 37.0º on the same day of the event Who have a confirmed diagnosis for SARS-CoV-2 in the two weeks prior to the event Report any symptoms suggestive of a SARS-CoV-2 infection in the 10 days prior to the study Who have been in contact with a person with a confirmed diagnosis of SARS-CoV-2 infection within two weeks prior to the event. Living with a person over 70 years of age (inclusive).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bonaventura Clotet Sala, PhD, MD
Organizational Affiliation
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Boris Revollo Barriga, PhD, MD
Organizational Affiliation
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Josep Mª LLIBRRE CODINA, PhD, MD
Organizational Affiliation
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Germans Trias i Pujol Hospital
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
34051886
Citation
Revollo B, Blanco I, Soler P, Toro J, Izquierdo-Useros N, Puig J, Puig X, Navarro-Perez V, Casan C, Ruiz L, Perez-Zsolt D, Videla S, Clotet B, Llibre JM. Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. Lancet Infect Dis. 2021 Oct;21(10):1365-1372. doi: 10.1016/S1473-3099(21)00268-1. Epub 2021 May 27.
Results Reference
derived

Learn more about this trial

Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures

We'll reach out to this number within 24 hrs